Latest News

Cleveland Clinic pilots HAP-E, guiding older adults to manage epilepsy and cognitive decline with lifestyle tools, meds support, and virtual access.

Findings from a 25-year analysis showed that tiapride was associated with significantly fewer adverse effect–related discontinuations than tetrabenazine in patients with Huntington disease chorea.

A sleep specialist and sleep patient advocate discussed diagnostic and patient-reported outcome measures that aim to better capture the cognitive, functional, and psychosocial burden of central disorders of hypersomnolence.

Optometrist DeAnn Fitzgerald, OD, discussed strategies to identify vision-related symptoms of TBI, the role of detailed history-taking, and the cultural considerations when caring for Hispanic patients.

Catch up on any of the neurology headlines you may have missed in June 2026, compiled into 1 place by the NeurologyLive® team.

A 10-protein serum signature identified through longitudinal proteomics significantly stratified relapse risk in NMOSD patients, with the 2 strongest markers showing an association with relapse more than 8 months out on average.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is retinal biomarkers for central nervous system disease!

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 3, 2026.

New phase 2b PARADIGM data showed PrimeC significantly reduced neuron-derived TDP-43 levels in patients with ALS while reinforcing previously reported improvements in disease progression and survival.

Tom Fuchs, MD, PhD, postdoctoral researcher at the MS Center at Amsterdam University Medical Center, shared his reaction to the European Commission's approval of tolebrutinib for nonrelapsing secondary progressive MS.

Results from the Baby-COMET study of avalglucosidase alfa in infantile-onset Pompe disease will support a planned US regulatory submission for a label extension, anticipated in the second half of 2026.

Twelve-month phase 1/2 data show SKY-0515-treated patients trending favorably versus natural history expectations across motor, functional, and cognitive endpoints, while 65% of patients and 50% of clinicians reported disease improvement.